Ultragenyx reports FY2022 net loss $707M, revenue $363M; guides 2023 rev $425-450M

Ultragenyx Pharmaceutical Inc.

2022-FY EPS reported -$10.12 revenue$363,329,000

FY2022 total revenue $363.3M (+3% YoY) from $351.4M in 2021.
Net loss $707.4M ($10.12/sh) vs $454.0M ($6.70) in 2021, driven by higher R&D and acquired IP.
Crysvita revenue $279.4M, Dojolvi $55.6M, Mepsevii $20.6M; cash $896.7M at year-end.
2023 guidance: total rev $425-450M; Crysvita $325-340M; Dojolvi $65-75M; net cash use <$400M.
Q4 net loss $151.8M ($2.16/sh) vs $122.5M ($1.79) in Q4 2021.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Ultragenyx Pharmaceutical Inc. reported Full year 2023 results: revenue Crysvita $325 million to $340 million; Dojolvi $65 million to $75 million. Guidance reaffirmed.

Period: Full year 2023
Revenue: Crysvita $325 million to $340 million; Dojolvi $65 million to $75 million
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

Total revenue in the range of $425 million to $450 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Ultragenyx Pharmaceutical Inc. reported Full year 2023 results: revenue Crysvita $325 million to $340 million; Dojolvi $65 million to $75 million. Guidance reaffirmed.

Period: Full year 2023
Revenue: Crysvita $325 million to $340 million; Dojolvi $65 million to $75 million
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

Crysvita revenue in the range of $325 million to $340 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Ultragenyx Pharmaceutical Inc. reported three months ended December 31, 2022 and year ended December 31, 2022 results: revenue $103.3 million for Q4 2022; $363.3 million for FY 2022, net income Net loss of $151.8 million for Q4 2022; Net loss of $707.4 million for FY 2022, EPS $(2.16) per share for Q4 2022; $(10.12) per share for FY 2022. Guidance reaffirmed.

Period: three months ended December 31, 2022 and year ended December 31, 2022
Revenue: $103.3 million for Q4 2022; $363.3 million for FY 2022
Net income: Net loss of $151.8 million for Q4 2022; Net loss of $707.4 million for FY 2022
EPS: $(2.16) per share for Q4 2022; $(10.12) per share for FY 2022
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Ultragenyx Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update

View on SEC.gov

Browse all earnings releases →

Ultragenyx Pharmaceutical Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-003048

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.